Suntinorexton

Suntinorexton
Identifiers
	IUPAC name N-2-fluoro-3-(3-fluorophenyl)phenylmethyl-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-ylethanesulfonamide;
CAS Number	2274802-89-8 ;
PubChem CID	137460941;
UNII	FF2NQ35DA4;
Chemical and physical data
Formula	C23H28F2N2O4S
Molar mass	466.54 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCS(=O)(=O)NC@H1CCN(C@H1CC2=C(C(=CC=C2)C3=CC(=CC=C3)F)F)C(=O)C(C)(C)O;
	InChI InChI=1S/C23H28F2N2O4S/c1-4-32(30,31)26-19-11-12-27(22(28)23(2,3)29)20(19)14-16-8-6-10-18(21(16)25)15-7-5-9-17(24)13-15/h5-10,13,19-20,26,29H,4,11-12,14H2,1-3H3/t19-,20-/m0/s1; Key:MQDUVMBBJZLFHF-PMACEKPBSA-N;

Suntinorexton (INNTooltip International Nonproprietary Name) is an experimental orexin receptor agonist.^[1] It acts as a selective agonist of the orexin OX₂ receptor and was described in 2019 in a patent by Takeda Pharmaceutical Company.^[2]

Referencesedit

^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 34 (1): 93–269. 2020. Proposed INN: List 123
^ WO application 2019027058, Kajita Y, Mikami S, Miyanohana Y, Koike T, Daini M, Oyabu N, Ogino M, Takeuchi K, Ito Y, Tokunaga N, Sugimoto T, Miyazaki T, Oda T, Hoashi Y, Hattori Y, Imamura K, "Heterocyclic compound and use therof", published 2019-02-07, assigned to Takeda Pharmaceutical Company.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Suntinorexton
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[WHO2020-1] "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 34 (1): 93–269. 2020. Proposed INN: List 123

[WO_2019027058-2] WO application 2019027058, Kajita Y, Mikami S, Miyanohana Y, Koike T, Daini M, Oyabu N, Ogino M, Takeuchi K, Ito Y, Tokunaga N, Sugimoto T, Miyazaki T, Oda T, Hoashi Y, Hattori Y, Imamura K, "Heterocyclic compound and use therof", published 2019-02-07, assigned to Takeda Pharmaceutical Company.

[1]

[2]

v t e Orexin receptor modulators
OX₁	Agonists: Orexin (A, B) Antagonists: ACT-335827 ACT-462206 ACT-539313 Almorexant AZD-4041 C4X-3256 (INDV-2000) CR-5542 Daridorexant Filorexant GSK-649868 (SB-649868) JNJ-61393215 Lemborexant RTIOX-276 SB-334867 SB-408124 Suvorexant TCS-1102 Vornorexant (ORN-0829, TS-142) YZJ-1139
OX₂	Agonists: Danavorexton (TAK-925) Firazorexton Orexin (A, B) SB-668875 Suntinorexton TAK-861 TAK-994 Antagonists: ACT-335827 ACT-462206 Almorexant Daridorexant EMPA Filorexant GSK-649868 (SB-649868) JNJ-10397049 Lemborexant MK-1064 MK-3697 MK-8133 Seltorexant Suvorexant TCS-1102 TCS-OX2-29 Vornorexant (ORN-0829, TS-142) YZJ-1139

Identifiers

IUPAC name N-2-fluoro-3-(3-fluorophenyl)phenylmethyl-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-ylethanesulfonamide
CAS Number	2274802-89-8^Y
PubChem CID	137460941
UNII	FF2NQ35DA4
Chemical and physical data
Formula	C₂₃H₂₈F₂N₂O₄S
Molar mass	466.54 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCS(=O)(=O)NC@H1CCN(C@H1CC2=C(C(=CC=C2)C3=CC(=CC=C3)F)F)C(=O)C(C)(C)O
InChI InChI=1S/C23H28F2N2O4S/c1-4-32(30,31)26-19-11-12-27(22(28)23(2,3)29)20(19)14-16-8-6-10-18(21(16)25)15-7-5-9-17(24)13-15/h5-10,13,19-20,26,29H,4,11-12,14H2,1-3H3/t19-,20-/m0/s1 Key:MQDUVMBBJZLFHF-PMACEKPBSA-N

See alsoedit

Referencesedit